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Synonyms:
Weil’s Disease, Swineherder’s
Disease, Rice Field Fever, Cane
Cutter Fever, Swamp Fever, Mud Fever,
Stuttgart Disease, Canicola
Etiology:
Leptospira interrogans (180 Serovars
In 18 Serogroups)
Leptospirosis is a bacterial disease
that affects humans and animals. It is
caused by bacteria of the genus
Leptospira. In humans it causes a
wide range of symptoms, and some
infected persons may have no
symptoms at all. Symptoms of
leptospirosis can include high fever,
severe headache, chil ls, muscle
aches, and vomiting, and may include
jaundice, red eyes, abdominal pain,
diarrhea, or a rash. If the disease is
not treated, the patient could develop
kidney damage, liver failure, and
respiratory distress. In rare cases
(generally those with concurrent
illnesses), death occurs.
Many of these symptoms can be
mistaken for other diseases.
Leptospirosis is confirmed by
laboratory testing of a blood or urine
sample.
Leptospirosis is a zoonotic disease;
it can be transmitted from animals to
humans. Outbreaks of leptospirosis
are usually caused by exposure to
water contaminated with the urine of
infected animals, which can get into
water or soil and can survive there for
Acute Retroviral Syndrome
Wayne Duffus, MD, PhD
Medical Director
DHEC, Division of STD/HIV
Primary human immunodeficiency virus (HIV) infection re-
fers to the period from initial infection with the human im-
munodeficiency virus to complete seroconversion. After
infection, there is a rapid rise in plasma viremia, with the
virus being disseminated widely in the body. This high
concentration of the virus has important public health im-
plications because it is a period of extreme infectious-
ness, and routine tests for the HIV antibody fail to detect
the new infection. There is a marked decrease from the
peak viremia after the initial rise, then a new viral set-point
is established. Individuals with the highest set-point viral
load have the most rapid rates of disease progression
and death.
Because of their nonspecific nature, the signs and symp-
toms of acute retroviral syndrome (ARS)  require a high
index of suspicion in order to be associated with new HIV-
infection. The signs and symptoms usually present within
days to weeks after initial exposure. They may last from a
few days to more than 10 weeks, but the duration is usu-
ally less than two weeks. Patients with the syndrome may
have fever, fatigue, rash, and pharyngitis as the most com-
mon symptoms. Other protean symptoms include lym-
phadenopathy, myalgia, headache, arthralgia, aseptic
meningitis, weight loss, depression, night sweats, gas-
trointestinal distress, and oral or genital ulcers. The oc-
currence and severity of symptoms during primary HIV
infection correlate with the rapidity of clinical and immu-
nologic decline. The nonspecific nature of these symp-
toms pose a major challenge to health care workers; this
emphasizes the need to obtain an accurate history of ex-
posure. Primary HIV infection should be considered in
any patient with possible HIV exposure who presents with
fever of unknown cause. The differential diagnosis for
these nonspecific signs and symptoms are HIV, infec-
tious mononucleosis, secondary syphilis, acute hepatitis
A or B, roseola or other viral exanthems, and toxoplasmo-
sis.
Although laboratory studies may reveal thrombocytopenia
and lymphopenia, atypical lymphocytes are infrequent, and
Leptospirosis
Kira A. Christian, DVM, MPH
DHEC, Division of Acute Disease Epidemiology
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these characteristic laboratory findings are not unique to
HIV infection. They may be observed in other acute viral
illnesses.  Note that the CD4 cell count usually decreases
during acute infection but may remain in the normal range.
The diagnosis of ARS is based on a positive HIV-1 RNA
level in the absence of a positive enzyme-linked
immunosorbent antibody assay (ELISA) and confirmatory
Western blot antibody test for HIV.  A blood sample should
be obtained for both HIV viral load testing and HIV ELISA
when a patient presents with the signs and symptoms of
ARS along with a compatible history of exposure. If these
laboratory tests return negative, an alternative diagnosis
should be sought.  However, both the HIV ELISA and HIV
viral load tests should be repeated two to four weeks after
the resolution of symptoms in high-risk persons.
Most persons with ARS do not expect to receive this
diagnosis even if they have had high risk sexual or IV drug
encounters. Health care workers should therefore be
skilled at sexual history taking and comfortable with
discussing substance use with their patients. They should
anticipate that patients will be angry, anxious, or fearful
when this diagnosis is discussed. Primary infection
presents a special window of opportunity within which to
exert a maximum impact on the spread of HIV. It is essential
to address the patient’s concerns and to explain planned
evaluation. Counseling about the importance of adopting
safer practices may instill prevention behaviors at a critical
time.
All patients with newly diagnosed HIV infection should be
linked to HIV medical care. The South Carolina Department
of Health and Environmental Control may be contacted if
assistance is needed.  However, in order to assure follow-
up, it is crucial that the health care worker be able to contact
the patient after discharge. In addition to helping the patient
access HIV medications upon diagnosis, public health
officials can use a network approach to identify persons
exposed to those with primary infections. By focusing
prevention efforts on the primary HIV infection interval, public
health officials could increase their leverage in slowing
the HIV epidemic.
(LEPTOSPIROSIS cont'd from Page 1)
weeks to months. Leptospires are ubiquitous in the
environment; almost all water sources can be
contaminated with leptospires. Infected wild and domestic
animals may continue to excrete the bacteria into the
environment continuously or every once in a while for a
few months up to several years.
Many different kinds of animals carry the bacterium; they
may become sick but sometimes have no symptoms.
Leptospira organisms have been found in cattle, pigs,
horses, dogs, rodents, and wild animals. Humans become
infected through contact with water, food, or soil containing
urine from these infected animals. This may happen by
swallowing contaminated food or water or through skin
contact, especially with mucosal surfaces, such as the
eyes or nose, or with broken skin. The disease is not
known to be spread from person to person. Drinking
contaminated water can also cause infection.
If a person’s pet has become infected, it most likely came
into contact with leptospires in the environment or infected
animals. The pet may have been drinking, swimming, or
walking through contaminated water. Because of
increased building and development into areas that were
previously rural, pets may be exposed to more wildlife,
such as raccoons, skunks, squirrels, opossums, or deer
that are infected with leptospirosis. Dogs also may pass
the disease to each other, but this happens very rarely.
The clinical signs of leptospirosis vary and are nonspecific
in animals; again, sometimes they do not have any
symptoms, just like with humans. Common clinical signs
reported in dogs include fever, vomiting, abdominal pain,
diarrhea, refusal to eat, severe weakness and depression,
stiffness, severe muscle pain, or inability to have puppies.
Generally younger animals are more seriously affected
than older animals. If a person feels that his or her pet
may be infected, contact the pet’s veterinarian immediately,
who can also order tests to detect the presence of
leptospiral antibodies.  However, if leptospirosis is
detected, confirmatory tests must be done to determine if
it is an acute infection.
The time between a person’s exposure to a contaminated
source and becoming sick is two days to four weeks. Illness
usually begins abruptly with fever and other symptoms.
Leptospirosis may occur in two phases; after the first
phase, with fever, chills, headache, muscle aches,
vomiting, or diarrhea, the patient may recover for a time
but become ill again. If a second phase occurs, it is more
severe; the person may have kidney or liver failure or
meningitis.  This phase is also call Weil’s disease.
The illness lasts from a few days to three weeks or longer.
Without treatment, recovery may take several months.
Leptospirosis occurs worldwide but is most common in
temperate or tropical climates. It is an occupational hazard
for many people who work outdoors or with animals, for
example, farmers, sewer workers, veterinarians, fish
workers, dairy farmers, or military personnel. It is a
recreational hazard for campers or those who participate
in outdoor sports in contaminated areas and has been
associated with swimming, wading, triathlons, and
whitewater rafting in contaminated lakes and rivers. The
incidence is also increasing among urban children.
Leptospirosis is treated with antibiotics, such as
doxycycline or penicillin, which should be given early in
the course of the disease. Intravenous antibiotics may be
required for persons with more severe symptoms.
Protective clothing or footwear should be worn by those
exposed to contaminated water or soil because of their
job or recreational activities.
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Control of Communicable Diseases Manual
CDC Healthy People Health Pets: http://www.cdc.gov/healthypets/
The Veterinary Information Network: http://www.vin.com
2005 Annual Report on Notifiable
Conditions in South Carolina
Libby Greene, MSN, APRN, BC
Director, Surveillance Section/Nurse Consultant
DHEC, Division of Acute Disease Epidemiology
The 2005 Annual Report on Notifiable Conditions has
been published and is available on the following DHEC
Internet Web sites:
· DHEC homepage at  http://www.scdhec.gov/
· DHEC Health Web page at http://
www.scdhec.gov/health/
· DHEC Bureau of Disease Control’s Web page
at http://www.scdhec.gov/health/disease/
index.htm
The Annual Report is published by the DHEC Bureau of
Disease Control and contains a brief narrative and
accompanying graphs displaying summary data for the
86 diseases or conditions that were reportable by law in
South Carolina in 2005. The report also contains
information on select outbreaks and special surveillance
projects in 2005 as well as a section on Trends and
Commentary Regarding Immunization Coverage for 2-Year
Old Children.  Useful Web links and bibliographic
references have been provided for readers interested in
additional information.
The DHEC Bureau of Disease Control hopes this report
will contribute to knowledge and understanding of the
challenges posed by infectious diseases of public health
importance in South Carolina.  The Annual Report of
Notifiable Conditions which were reportable in South
Carolina in 2006 should be available by the end of 2007.
Merck Vaccine Patient Assistance
Program - What you need to know
Jesse Greene, MSN, RN
Director
DHEC, Immunization Division
Vaccine-preventable infections of adults represent a
continuing cause of morbidity and mortality.  The Centers
for Disease Control and Prevention (CDC) estimates the
cost of this health burden to society1 at approximately $10
billion per year.  Merck and Company Inc. makes safe and
effective vaccines against the following diseases: human
papillomavirus, measles, mumps, rubella, streptococcus
pneumoniae, hepatitis A and B viruses, varicella zoster,
and herpes zoster (shingles).  Because some people
cannot afford to pay for these vaccinations or do not have
health insurance, Merck and Company Inc. has introduced
a “Vaccine Patient Assistance Program”.
How does the program work?
This program is available in the private medical community
only and not in public health settings.  Patients may qualify
if they are residents of the U.S., age 19 years or older, do
not have health insurance, and cannot afford to pay for
vaccination.  The program announcement states, “You may
qualify if you have a household income of $19,600 or less
for individuals or $26,400 or less for couples.  Income
levels may vary for larger households.”
A “Merck Vaccine Patient Assistance Program Application”
must be completed and signed by the patient and the
doctor, nurse practitioner, or physician assistant.  The two-
page application is faxed by the health care provider to the
Merck program for approval.  Merck will grant assistance
via a return fax to the health care provider with confirmation
that Merck will replace the doses of vaccine administered
to approved patients via quarterly shipments to the licensed
prescriber.
What vaccines are covered?
GARDASIL® [Quadrivalent Human Papillomavirus (Types
6, 11, 16, 18) Recombinant Vaccine]
M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine
Live)
PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent)
RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)]
VAQTA® (Hepatitis A Vaccine, Inactivated)
VARIVAX® [Varicella Virus Vaccine Live (Oka/Merck)]
ZOSTAVAX® [Zoster Vaccine Live (Oka/Merck)]
For more information contact Merck Vaccine Patient
Assistance Program (800) 293-3881 or http://
www.merckhelps.com
References
1.    Executive Summary - Actions to Strengthen Adult and
Adolescent Immunization Coverage in the United
States: Policy Principles of the Infectious Diseases
Society of America. Clinical Infectious Diseases 2007;
44:1529-31.
2.    MERCK Vaccine Patient Assistance Program patient
information brochure.
Digitized by South Carolina State Library
Epi Notes     Page 4               Summer 2007
CDC Annual Report
“Annual Assessment of Progress Toward Goals to Prevent Perinatal HBV
Transmission”
Elona Rhame, RN, MSN, MPH
Hepatitis Program Manager/Nurse Consultant
DHEC, Division of STD/HIV
Each year the South Carolina Department of Health and Environmental Control’s (DHEC) Immunization Division
completes the required CDC report - “Annual Assessment of Progress Toward Goals to Prevent Perinatal HBV
Transmission”.   This report was submitted to CDC in March 2007 for infants born in 2005.
The graph below shows DHEC data from 1997 through 2005.  The CDC estimates that approximately 200 infants are
born to HBsAg positive women in South Carolina each year.  These expected births are calculated from state birth data
using HBsAg prevalence estimates of specific ethnic categories.  The number of infants tracked (case managed) in
South Carolina falls below the CDC estimate; however, infants tracked for Perinatal Hepatitis B Case Management in
South Carolina dramatically increased in 2005.  This increase is believed to be due primarily to DHEC’s enhanced
disease surveillance – “Carolina’s Health Electronic Surveillance System” (CHESS), to more prompt and complete
reporting to DHEC by health care providers, and to enhanced case finding by DHEC regional staff.
In 2005 DHEC received reports on 88 infants born to HBsAg positive women.  Of the 88 infants that were case managed
in South Carolina in 2005, only 43 (49%) completed post vaccination serologic testing at the time the CDC report was
submitted.
CDC recommendations for management of infants born to women who are HBsAg positive include:
1. Administer single-antigen hepatitis B vaccine and Hepatitis B Immune Globulin (HBIG) by 12 hours of birth.
2. Complete the vaccine series according to recommended schedule.
3. Perform postvaccination testing for anti-HBs and HBsAg after completion of the vaccine series, at age 9-18
months.
All medically stable infants weighing greater than or equal to 2000 grams at birth and born to HBsAg-negative mothers
should receive the first dose of hepatitis B vaccine before hospital discharge.  According to the 2005 National Immunization
Survey, the estimated vaccination coverage for hepatitis B vaccine among children from birth to 2 days of age was 56.8+/
- 7.3.
Following are data regarding hepatitis B infection during pregancy:
•    Number of  women who had Hepatitis B infections present during this pregnancy:     100
•    Number of infants who received the Birth Dose of Hepatitis B vaccine:     37,026
•    Number of infants who received Hepatitis B Immune Globulin (HBIG) within 12 hours of birth:     99
•    Total births in 2005:   55,673 (provisional)
                                      Perinatal Hepatitis B Prevention Program
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The 2007-2008 Exclusion Lists for school and out-of-home child care were posted on the DHEC Web site in March of
this year.  These lists, which are effective July 1, 2007, reflect a thorough review of exclusion criteria following the
publication of the 2006 Red Book (AAP).  They also reflect changes in epidemiology of some skin infections and
nationwide experience with recent outbreaks of vaccine-preventable illnesses.
Before addressing changes in the Exclusion Lists, it may be helpful to review their purpose.  The School and Child Care
Exclusion Lists were developed by DHEC pursuant to S.C. Regulation #61-20, which requires that DHEC publish each
year an “Official School and Child Care Exclusion List of Contagious and Communicable Diseases.”  Regulation #61-
20 further requires that students should be excluded from school attendance if they have one or more of the conditions
in the lists.  These lists are published on the DHEC Web site and are sent to schools for copying and distribution to
parents.  In addition to describing exclusion criteria, the lists also indicate which illnesses (as individual cases or
outbreaks) are reportable to DHEC.
 
 
 
SC Law: Children with contagious diseases shall not attend school or 
childcare in out-of-home settings. 
 
No superintendent, principal, teacher of any school or provider of child care in an out-of-home 
setting, as defined in S.C. Code Ann. Section 20-7-2700, and no parent, master, or guardian of 
any child or minor shall permit any such child or minor having any contagious or infectious 
disease or syndrome requiring isolation to attend any private, parochial, church, or Sunday 
school when the disease or syndrome of the child or minor is on the Official School and Child 
Care Exclusion List of Contagious or Communicable Diseases. For the purpose of this 
regulation, the Department of Health and Environmental Control shall publish in January of each 
year an Official School and Child Care Exclusion List of Contagious or Communicable Diseases, 
to include specific conditions for duration of school or child care exclusion and criteria for return 
for a child with any of these excludable diseases. (Regulation 61-20) 
http://www.scstatehouse.net/coderegs/c061a.htm 
 
 
To Whom the Lists Apply
The School Exclusion List applies to those students in grades 1-12 who are not medically fragile.  The Child Care
Exclusion List should be used for students in grades K-3, K-4, and K-5, as well as students in grades 1-12 who are
designated as being medically fragile.  For the purposes of school exclusion, “medically fragile students” are those
with special health care needs or developmental delays who require close assistance with feeding or other personal
hygiene activities by which communicable illnesses may easily be spread.
The Exclusion List criteria are aimed at generally healthy children.  Immunocompromised children who have an
excludable condition or exposure may need longer periods of exclusion, subject to recommendations by their health
care provider(s).  Nothing in these criteria precludes the exercise of the professional judgment of Local Education
Agency medical and/or nursing staff to protect the health of students.
Changes in the School and Child Care Exclusion Lists for the 2007-2008 School Year
Michelle L. Myer, MSN, RN, CPNP
Epidemiology Nurse Consultant
DHEC, Division of Acute Disease Epidemiology
   (Continued on Page 6)
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General Principles
?Infected children should be excluded from school until they are no longer considered contagious.
?If a student does not respond to treatment for an excludable condition, the health care provider or public health
department may suggest longer periods of exclusion.
?Exclusion for children exposed to certain serious illnesses will vary, depending on the availability of immunization or
antibiotic prophylaxis, timing of exposure relative to immunization, and severity of illness.
?Because mild illness is common among children, most children will not need to be excluded from their usual source
of child care for mild respiratory tract illnesses, since transmission is likely to have occurred before symptoms
developed in the child.
General Changes for 2007-2008
The School and Child Care Exclusion Lists and simplified Parent Brochures are available at the DHEC Web site (http:/
/www.dhec.gov/health/disease/exclusion.htm.)  This article will focus only on changes found in the 2007-2008 lists.
? Arrangement:  The lists are now arranged alphabetically.  However, general symptoms that may indicate severe
illness still appear at the beginning of both lists.
? Age-Specific Criteria:  For some illnesses, school exclusion criteria are different for children grades 1-5 and for
older students.  This is based on assumptions about maturity of children, independence and hygiene related to
toileting, and differences in patterns of interactions among students in elementary schools as opposed to
middle or high school students.
Changes in Specific Illnesses/Conditions:
? Abdominal Pain: Exclusion for persistent abdominal pain (continuing for two or more hours) or intermittent
abdominal pain associated with fever, dehydration, or other systemic symptoms, was added to the Child Care
Exclusion List.
? Diarrheal Illness:
o Lab testing and antibiotic therapies for E. coli, Salmonella typhi, and Shigella were clarified for children in
child care.
o Children in child care and school students do not have to be excluded for diarrhea that persists following
completion of antimicrobial therapy for an enteric illness.  Since symptoms may persist well after antibiotics
are completed, some children were being excluded for several weeks following initial illness.
o Exclusion is required for first- through fifth- graders with E. coli and Salmonella typhi until 24 hours without
a diarrheal stool.  School children with Shigella are excluded until diarrheal symptoms cease.
o Exclusion for diarrhea, unless it is caused by E. coli, Salmonella typhi, or Shigella is not mandatory for
middle and high schoolers, unless a student is determined to be contributing to the spread of illness in the
school setting, or unless the student has uncontrolled diarrhea or stools containing blood or mucus.
The exclusion criterion for E. coli in school-age children is less stringent that that described in the 2006 Red
Book.  South Carolina’s policy is based on epidemiological evidence that suggests that in-school transmission
of E. coli infection is uncommon among un-diapered children.  There may be an academic burden imposed by
lengthy exclusions while awaiting multiple negative culture results.  DHEC may change this exclusion criterion in
the event of an outbreak or cluster of diarrheal illness attributable to E. coli.
? Mumps: Children with mumps are excluded for five (not nine) days following onset of parotid gland swelling.
? Pertussis:
o Children with pertussis are excluded until completion of five days of appropriate antibiotic therapy, unless
initially diagnosed with pertussis past the infectious period (21 or more days after cough onset, or six weeks
after cough onset for infants).
o Exclusion of persons exposed to pertussis who now have cough illness should be considered pending
evaluation by a physician.  If the physician or DHEC recommends exclusion, exclude until (a) completion of
five days of appropriate antimicrobial therapy or (b) until 21 days after last contact with an infected person.
? Staphylococcal (including MRSA and Impetigo) and Streptococcal Skin Infections
Recent studies have indicated that up to 50 percent of impetigo lesion may be attributable to MRSA (Methicillin-
resistant Staphylococcus aureus).  Outbreaks of Staph and Strep skin infections, especially among children
sharing equipment or participating in close contact sports, have increased in the past few years in South Carolina.
These conditions were added to the Exclusion Lists as follows:
Continued on Page 7)
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o Impetigo:  Exclude children with Impetigo, whose lesions cannot be covered, until the student has received
48 hours of effective antimicrobial treatment, lesions are showing signs of healing (decreasing in size), and
oozing has stopped.
o Other Staphylococcal or Streptococcal Skin Infections (includes MRSA):
• Exclude children with draining lesions that cannot be covered with a dressing, or draining lesions that
are covered with a dressing but drainage saturates the dressing, until drainage stops and the child has
received at least 48 hours of effective antimicrobial treatment.
• Children who do not have draining lesions may return to school after they have received at least 48 hours
of effective antimicrobial treatment and lesions are showing signs of healing (decreasing in size.)
• Children with lesions on uncovered skin  or with lesions that are draining or oozing, even if covered, may
not participate in close contact sports or other athletic activities.
• Contact precautions, including appropriate disposal of infective materials, must be used if/when dressings
are changed in the school or child care setting.
DHEC may change these recommendations in the event of outbreaks or clusters of Staph or Strep skin infections.
? Varicella:  Because children with breakthrough Varicella (typically seen in previously immunized children) often
do not develop the typical vesicles or crusting of lesions, children with mild or breakthrough Varicella disease
should be excluded from school until lesions fade away and no new lesions appear.
? Exposure to Vaccine Preventable Illnesses:  Exclusion for exposure and re-admission criteria post-immunization
were added for students exposed to Measles, Mumps, Rubella, and Varicella.
Exclusion Not Required
Several conditions were added to those for which exclusion is not required:
? Chronic Hepatitis B
? Chronic Hepatitis C
? HIV infection
? Respiratory Syncytial Virus.
The Exclusion Lists point providers and schools to the DHEC STD/HIV Division (1.800.322.AIDS) for consultation
regarding infection control issues raised by the presence of students with blood-borne illnesses (HIV, chronic Hepatitis
B, chronic Hepatitis C, etc.) in school or out-of-home child care.
The Division of Acute Disease Epidemiology would appreciate any feedback from health care providers on the School
or Child Care Exclusion Lists.  These will next be revised at the end of January 2008 for the 2008-2009 school year.
Contact us at: Exclusion@dhec.sc.gov or (803) 898-0861 with any questions or comments.
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Condition Confirmed Probable Total 
Animal Bite—PEP Recommended 105 * 105 
Aseptic meningitis 40 1 41 
Brucellosis 2 0 2 
Campylobacteriosis 46 1 47 
Ciguatera fish poisoning 1 0 1 
Cryptosporidiosis 25 * 25 
Cyclosporiasis 1 * 1 
Dengue Fever 0 1 1 
Ehrlichiosis- human granulocytic 1 0 1 
Ehrlichiosis- human monocytic 0 0 0 
Ehrlichiosis- human- other&unspec 0 0 0 
Encephalitis- West Nile 0 0 0 
Enterohem. E.coli O157:H7 0 0 0 
Enterohem.E.coli shigatox+- ?serogrp 0 0 0 
Enterohem.E.coli- shigatox+- non-O157 0 0 0 
Giardiasis 36 0 36 
Group A Streptococcus- invasive 62 0 62 
Group B Streptococcus- invasive 14 0 14 
Haemophilus influenzae- invasive 31 0 31 
Hemolytic uremic synd- postdiarrheal 1 0 1 
Hepatitis A- acute 5 0 5 
Hepatitis B- acute 45 3 48 
Hepatitis B virus infection- chronic 129 147 276 
Hepatitis C- acute 0 0 0 
Hepatitis C Virus Infection- past or present 1797 446 2243 
Hepatitis Delta co- or super-infection- acute 0 0 0 
Hepatitis E- acute 1 0 1 
Influenza- human isolates 68 0 68 
Legionellosis 8 1 9 
Listeriosis 2 0 2 
Lyme disease 9 1 10 
Malaria 4 0 4 
Mumps 0 0 0 
Neisseria meningitidis- invasive (Mening. disease) 9 0 9 
Pertussis 32 12 44 
Rocky Mountain spotted fever 8 12 20 
S. aureus- coag+- meth- or oxi- resistant (MRSA) 1 0 1 
Salmonellosis 302 3 305 
Shiga toxin-producing Escherichia coli (STEC) 0 0 0 
Shigellosis 36 0 36 
Strep pneumoniae- invasive 194 1 195 
Streptococcal disease- invasive- other 7 0 7 
Tetanus 0 0 0 
Toxic-shock syndrome- staphylococcal 0 0 0 
Varicella (Chickenpox) 418 262 680 
Vibrio parahaemolyticus 1 0 1 
Vibrio spp.- non-toxigenic- other or unspecified 3 0 3 
Vibrio vulnificus infection 0 0 0 
West Nile Fever 0 0 0 
Yersiniosis 6 1 7 
* Probable case status is not allowed for this condition. 
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